Duality Biotherapeutics, Inc. (HKG:9606)
Hong Kong · Delayed Price · Currency is HKD 204.20
-3.80 (-1.83%)
Jul 9, 2026, 4:08 PM HKT
Duality Biotherapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Duality Biotherapeutics stock has a consensus rating of "Strong Buy" and an average price target of $434.26. The average 1-year stock price forecast is 112.66% higher than the current stock price, while the lowest is $370.09 (+81.24%) and the highest is $508.08 (+148.81%).
Price Target: $434.26 (+112.66%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 10, 2026.
Analyst Ratings
The average analyst rating for Duality Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst GF Securities No rating | GF Securities | Buy Maintains $520.49 | Buy | Maintains | $520.49 | +154.89% | Apr 10, 2026 |
Unknown Analyst Guotai Haitong No rating | Guotai Haitong | Buy Maintains $457.74 | Buy | Maintains | $457.74 | +124.16% | Apr 9, 2026 |
Unknown Analyst KeyBanc No rating | KeyBanc | Buy Maintains $425.63 | Buy | Maintains | $425.63 | +108.44% | Apr 1, 2026 |
| CMB International Securities | CMB International Securities | Buy Maintains $383.47 | Buy | Maintains | $383.47 | +87.79% | Mar 30, 2026 |
Unknown Analyst CICC No rating | CICC | Buy Maintains $430.00 | Buy | Maintains | $430.00 | +110.58% | Mar 27, 2026 |
Financial Forecast
Revenue This Year
1.60B
from 1.85B
Decreased by -13.42%
Revenue Next Year
1.43B
from 1.60B
Decreased by -10.98%
EPS This Year
-4.15
from -39.80
EPS Next Year
-6.19
from -4.15
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.0B | ||
| Avg | 1.6B | ||
| Low | 1.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6.8% | ||
| Avg | -13.4% | ||
| Low | -44.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.88 | ||
| Avg | -4.15 | ||
| Low | -10.30 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |